These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16362085)

  • 1. Molecule of the month. Deferasirox.
    Drug News Perspect; 2005 Sep; 18(7):462. PubMed ID: 16362085
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox and children: From clinical trials to the real world.
    Origa R; Zappu A; Foschini ML; Leoni G; Morittu M; Moi P; Corpino M; Dessì C
    Am J Hematol; 2016 Jun; 91(6):E304-5. PubMed ID: 26950047
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
    Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
    Yusuf B; McPhedran P; Brewster UC
    Am J Kidney Dis; 2008 Sep; 52(3):587-90. PubMed ID: 18534729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A; Stone RM
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract]   [Full Text] [Related]  

  • 10. Deferasirox: an update.
    Porter JB
    Hemoglobin; 2009; 33 Suppl 1():S70-5. PubMed ID: 20001635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox desensitization.
    Bruner KE; White KM
    J Allergy Clin Immunol Pract; 2016; 4(1):171-2. PubMed ID: 26489716
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 14. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
    Pongtanakul B; Viprakasit V
    Blood Cells Mol Dis; 2013 Aug; 51(2):96-7. PubMed ID: 23566753
    [No Abstract]   [Full Text] [Related]  

  • 15. Deferasirox (Exjade): a new iron chelator.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
    [No Abstract]   [Full Text] [Related]  

  • 16. Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
    Even-Or E; Becker-Cohen R; Miskin H
    Am J Hematol; 2010 Feb; 85(2):132-4. PubMed ID: 20052747
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F; Phatak P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
    Fernandes JL
    Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.